1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

31 Jul 2020
Admin
News Article

Boehringer Ingelheims EMPEROR-Reduced Phase II Trial Of Empagliflozin In Adults With Heart Failure Meets Primary Endpoint

Boehringer Ingelheim has said that its EMPEROR-Reduced phase II trial in adults with heart failure with reduced ejection fraction, with and without diabetes met its primary endpoint, demonstrating superiority with empagliflozin (10mg) compared to placebo. It reduced the risk for the composite of cardiovascular death or hospitalization due to heart failure, when added to standard of care.The safety profile in all participants independent of type 2 diabetes was similar to the known safety profile of empagliflozin.“Heart failure is a common, but very serious chronic cardiovascular disorder, and it causes substantial disability while threatening the lives of millions of people worldwide. The results of the EMPEROR-Reduced trial indicate that SGLT2 inhibitors have the potential to become new standard of care for this disease, which will be a meaningful addition to the currently established treatments,” said Dr Milton Packer, chair of the executive committee for the EMPEROR Programme and Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center, Dallas, Texas. Heart failure is the leading cause of hospitalization in the US and Europe, and the number of patients across Asia is also increasing. Heart-failure related mortality is particularly high in Indian patients, as observed in INTER-CHF study. The risk of death in people with heart failure rises with each hospital admission.“One in five people can expect to develop heart failure in their lifetime, so it is very encouraging to see these positive results from the EMPEROR-Reduced trial demonstrating that empagliflozin improves heart failure outcomes,” said Dr Waheed Jamal, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim.. “We are excited to share the full results and are working tirelessly to explore how empagliflozin can improve the lives of people living with heart failure,” he added.India bears a huge burden of heart-failure, not only due to the size of our population, but also the increased risk conferred by several predisposing factors. For instance, hypertension, diabetes, ischaemic heart disease, and/or kidney disease are widely prevalent in our adult population. Not only do these risk-factors affect our Indian adults at relatively younger ages, but these also remain inadequately controlled. This myriad of cardio-renal-metabolic risks naturally lead to an increased predisposition for heart-failure, in our population,” said Dr. Shraddha Bhure, medical director , Boehringer Ingelheim India.Full results from the EMPEROR-Reduced trial will be presented in a hot line session at the European Society of Cardiology (ESC) congress 2020, 29 August. A second trial, EMPEROR-Preserved, will explore the effect of empagliflozin on cardiovascular death and hospitalization for heart failure in adults with heart failure with preserved ejection fraction. This is an area of high unmet need as there are currently no treatment options available for people with heart failure with preserved ejection fraction. EMPEROR-Preserved results are expected in 2021

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!